Clinical Trial

Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 1, 2023 (before its estimated May 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a multicenter, single arm, phase II study aimed at evaluating ibrutinib therapy for the treatment of AIHA in patients with CLL/SLL or CLL-like MBL.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-01-12.
Status change: Not Yet Recruiting → Recruiting 2023-11-28
Trial Details
NCT Number NCT05694312
Lead Sponsor Gruppo Italiano Malattie EMatologiche dell'Adulto
Conditions Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Monoclonal B-Cell Lymphocytosis CLL-Type
Enrollment 45 participants
Start Date 2023-11-24
Primary Completion 2025-05 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2023-12-01